Corrigendum: Correction to MR imaging and MR spectroscopic imaging in the pre-treatment evaluation of prostate cancer (Radiol (2005) 78 (S103-S111) DOI: 10.1259/bjr/11253478);MR imaging and MR spectroscopic imaging in the pre-treatment evaluation of prostate cancer

British Journal of Radiology

Volumn 78, Issue SPEC. ISS. 2, 2005, Pages

  Hricak, H ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER DIAGNOSIS; CANCER INVASION; CANCER SIZE; CANCER STAGING; CLINICAL PRACTICE; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; IMAGE ANALYSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PATIENT CODING; PATIENT MONITORING; PREDICTION; PROSTATE BIOPSY; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOLOGIST; REVIEW; SENSITIVITY AND SPECIFICITY; SURGEON; TREATMENT PLANNING;

EID: 29644443518     PISSN: 00071285     EISSN: 1748880X     Source Type: Journal    
DOI: 10.1259/bjr.11253478.c     Document Type: Erratum

References (55)

1. Corte Fernandez, N. Prostate Cancer. Available at: http://www.bbc.co.uk/health/mens/cond_prostate_cancer.shtml [Accessed November 16, 2004.]
2. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
3. Physician Data Query (PDQ) of the National Cancer Institute: Treatment options for health professionals. Prostate Cancer. Available at: http://www.cancer.gov [Accessed February 20, 2004.]
4. Lu-Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997;349:906-10.
5. Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347:781-9.
6. Gilligan T, Kantoff PW. Chemotherapy for prostate cancer. Urology 2002;60:94-100.
7. Thompson IM, Seay TM. Will current clinical trials answer the most important questions about prostate adenocarcinoma? Oncology (Huntingt) 1997;11:1109-17.
8. World Health Organization. Stewart BW, Kleihues P, editors. World Cancer Report. Lyon: International Agency for Research on Cancer, 2003.
9. Barentsz JO, Engelbrecht M, Jager GJ, et al. Fast dynamic gadolinium-enhanced MR imaging of urinary bladder and prostate cancer. J Magn Reson Imaging 1999;10:295-304.
10. Oyen RH. Dynamic contrast-enhanced MRI of the prostate: is this the way to proceed for characterization of prostatic carcinoma? Eur Radiol 2003;13:921-4.
11. Hricak H, White S, Vigneron D, et al. Carcinoma of the prostate gland: MR imaging with pelvic phased array coil versus integrated endorectal-pelvic phased-array coils. Radiology 1994;193:703-9.
12. Ikonen S, Kivisaari L, Vehmas T, et al. Optimal timing of post-biopsy MR imaging of the prostate. Acta Radiol 2001;42:70-3.
13. White S, Hricak H, Forstner R, et al. Prostate cancer: effect of postbiopsy hemorrhage on interpretation of MR images. Radiology 1995;195:385-90.
14. Brown TR, Kincaid BM, Ugurbil K. NMR chemical shift imaging in three dimensions. Proc Natl Acad Sci USA 1982;79:3523-6.
15. Star-Lack J, Nelson SJ, Kurhanewicz J, Huang LR, Vigneron DB. Improved water and lipid suppression for 3D PRESS CSI using RF band selective inversion with gradient dephasing (BASING). Magn Reson Med 1997;38:311-21.
16. Schnall MD, Pollack HM. Magnetic resonance imaging of the prostate. Urol Radiol 1990;12:109-14.
17. 3 ) spatial resolution. Radiology 1996;198:795-805.
18. Males RG, Vigneron DB, Star-Lack J, et al. Clinical application of BASING and spectral/spatial water and lipid suppression pulses for prostate cancer staging and localization by in vivo 3D 1H magnetic resonance spectroscopic imaging. Magn Reson Med 2000;43:17-22.
19. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 2003;349:335-42.
20. Wefer AE, Hricak H, Vigneron DB, et al. Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 2000;164: 400-4.
21. Rabbani F, Stroumbakis N, Kava BR, Cookson MS, Fair WR. Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol 1998;159:1247-50.
22. Obek C, Louis P, Civantos F, Soloway MS. Comparison of digital rectal examination and biopsy results with the radical prostatectomy specimen. J Urol 1999;161:494-8; discussion 498-9.
23. Zakian KL, Eberhardt S, Hricak H, et al. Transition zone prostate cancer: metabolic characteristics at 1H MR spectroscopic imaging - initial results. Radiology 2003;229:241-7.
24. Beyersdorff D, Taupitz M, Winkelmann B, et al. Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging. Radiology 2002;224: 701-6.
25. Scheidler J, Hricak H, Vigneron DB, et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging - clinicopathologic study. Radiology 1999;213: 473-80.
26. Mullerad M, Hricak H, Kuroiwa K, et al. Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer. J Urol (In Press).
27. Terris MK. Prostate biopsy strategies: past, present, and future. Urol Clin North Am 2002;29:205-12.
28. Cookson MS, Fleshner NE, Soloway SM, Fair WR. Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. J Urol 1997;157:559-62.
29. Steinberg DM, Sauvageot J, Piantadosi S, Epstein JI. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol 1997;21:566-76.
30. Zakian KL, Sircar K, Hricak H, et al. Correlation of proton MR spectrosocpic imaging with gleason score grade based on step-section pathology after radical prostatectomy. Radiology 2005;234:804-14.
31. American Joint Committee on Cancer. Prostate. In: Greene FL, Page DL, Fleming ID, et al, editors. AJCC Cancer Staging Manual, 6th edn. New York: Springer, 2002;309-16.
32. Engelbrecht MR, Jager GJ, Laheij RJ, Verbeek AL, van Lier HJ, Barentsz JO. Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis. Eur Radiol 2002;12:2294-302.
33. Wang L, Mullerad M, Chen HN, et al. Prostate cancer: incremental value of endorectal MR imaging findings for prediction of extracapsular extension. Radiology 2004;232:133-9.
34. Outwater EK, Petersen RO, Siegelman ES, Gomella LG, Chernesky CE, Mitchell DG. Prostate carcinoma: assessment of diagnostic criteria for capsular penetration on endorectal coil MR images. Radiology 1994;193:333-9.
35. Yu KK, Hricak H, Alagappan R, Chernoff DM, Bacchetti P, Zaloudek CJ. Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging: multivariate feature analysis. Radiology 1997;202:697-702.
36. Yu KK, Scheidler J, Hricak H, et al. Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging. Radiology 1999;213:481-8.
37. Claus FG, Hricak H, Hattery RR. Pretreatment evaluation of prostate cancer: role of MR imaging and 1H MR spectroscopy. Radiographics 2004;24 Suppl. 1:S167-80.
38. Mullerad M, Hricak H, Wang L, Chen HN, Kattan MW, Scardino PT. Prostate cancer: detection of extracapsular extension by genitourinary and general body radiologists at MR imaging. Radiology 2004;232:140-6.
39. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003;348:2491-9.
40. Bellin MF, Roy C, Kinkel K, et al. Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles - initial clinical experience. Radiology 1998;207:799-808.
41. Hricak H, Wang L, Wei DC, et al. The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy. Cancer 2004;100:2655-63.
42. Coakley FV, Eberhardt S, Wei DC, et al. Blood loss during radical retropubic prostatectomy: relationship to morphologic features on preoperative endorectal magnetic resonance imaging. Urology 2002;59:884-8.
43. Coakley FV, Eberhardt S, Kattan MW, Wei DC, Scardino PT, Hricak H. Urinary continence after radical retropubic prostatectomy: relationship with membranous urethral length on preoperative endorectal magnetic resonance imaging. J Urol 2002;168:1032-5.
44. Leibel SA, Fuks Z, Zelefsky MJ, et al. Intensity-modulated radiotherapy. Cancer J 2002;8:164-76.
45. Pollack A, Hanlon A, Horwitz EM, Feigenberg S, Uzzo RG, Price RA. Radiation therapy dose escalation for prostate cancer: a rationale for IMRT. World J Urol 2003;21: 200-8.
46. Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Uzzo RG, Hanks GE. Prostate cancer radiotherapy dose response: an update of the Fox Chase experience. J Urol 2004;171: 1132-6.
47. Kuban D, Pollack A, Huang E, et al. Hazards of dose escalation in prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys 2003;57:1260-8.
48. Padhani AR, Nutting CM. Why do we need more accurate intraprostatic localization of cancer? Br J Radiol 2003;76:585-6.
49. Roach M 3rd, Faillace-Akazawa P, Malfatti C, Holland J, Hricak H. Prostate volumes defined by magnetic resonance imaging and computerized tomographic scans for three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 1996;35:1011-8.
50. Debois M, Oyen R, Maes F, et al. The contribution of magnetic resonance imaging to the three-dimensional treatment planning of localized prostate cancer. Int J Radiat Oncol Biol Phys 1999;45:857-65.
51. Rasch C, Barillot I, Remeijer P, Pouw A, van Herk M, Lebesque JV. Definition of the prostate in CT and MRI: a multi-observer study. Int J Radiat Oncol Biol Phys 1999;43:57-66.
52. Steenbakkers RJ, Deurloo KE, Nowak PJ, Lebesque JV, van Herk M, Rasch CR. Reduction of dose delivered to the rectum and bulb of the penis using MRI delineation for radiotherapy of the prostate. Int J Radiat Oncol Biol Phys 2003;57:1269-79.
53. Mizowaki T, Cohen GN, Fung AY, Zaider M. Towards integrating functional imaging in the treatment of prostate cancer with radiation: the registration of the MR spectroscopy imaging to ultrasound/CT images and its implementation in treatment planning. Int J Radiat Oncol Biol Phys 2002;54:1558-64.
54. DiBiase SJ, Hosseinzadeh K, Gullapalli RP, et al. Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2002;52:429-38.
55. D'Amico AV, Whittington R, Malkowicz B, et al. Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer. J Urol 2000;164:759-63.